BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 10911422)

  • 1. [Taxol (paclitaxel) as second-line therapy in breast and ovarian cancer].
    Borovik R; Steiner M; Atad J; Sneiderman B; Rosenberg T; Palti S
    Harefuah; 1998 Apr; 134(8):605-8, 671. PubMed ID: 10911422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paclitaxel in platinum-resistant ovarian cancer patients. Argentine Multicenter Taxol Group.
    Ezcurdia L; Jovtis SL; Mickiewicz E; Temperley G; Rondinón M; Blajman C; Cóppola FS; Lewi D; Cazap E; Breier S; Fasce H; Fein L; Polera J; Triguboff E; Uranga G; Pasccón G; Luchina AM; Martínez CA; Politi PM; Rubio G; Alvarez AM
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-53-S15-56. PubMed ID: 9346223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Taxol as second-line treatment in patients with advanced ovarian cancer after platinum-based first-line chemotherapy.
    Mayerhofer K; Kucera E; Zeisler H; Speiser P; Reinthaller A; Sevelda P
    Gynecol Oncol; 1997 Jan; 64(1):109-13. PubMed ID: 8995557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An ongoing European organization for research and treatment of cancer crossover trial comparing single-agent paclitaxel and doxorubicin as first- and second-line treatment of advanced breast cancer.
    Piccart-Gebhart MJ; Bruning P; Gamucci T; Klijn J; Roy JA; Awada A; Kusenda Z; Van Vreckem A; Paridaens R
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):11-5. PubMed ID: 8893893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Taxol hypersensitivity: rapid retreatment is safe and cost effective.
    Olson JK; Sood AK; Sorosky JI; Anderson B; Buller RE
    Gynecol Oncol; 1998 Jan; 68(1):25-8. PubMed ID: 9454655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A phase II clinical study of China-made paclitaxel in the treatment of cancer patients].
    Wu H; Guan Z; Lin T
    Zhonghua Zhong Liu Za Zhi; 1998 Mar; 20(2):148-52. PubMed ID: 10920970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Taxol].
    Kühnle H
    Zentralbl Gynakol; 1996; 118(10):580. PubMed ID: 8999717
    [No Abstract]   [Full Text] [Related]  

  • 8. One-hour paclitaxel infusions: review of safety and efficacy.
    Greco FA; Thomas M; Hainsworth JD
    Cancer J Sci Am; 1999; 5(3):179-91. PubMed ID: 10367176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Phase II study of paclitaxel (BMS-181339) in patients with ovarian cancer by 3-hour intravenous infusion].
    Noda K; Ikeda M; Kudo R; Nishiya I; Yajima A; Tanaka K; Kodama S; Takahashi T; Tokunaga A; Satoh I; Nozawa S; Taketani Y; Terashima Y; Isonishi S; Takeda Y; Nishijima M; Kuroshima Y; Fujii S; Izumi R; Tamaya T; Mori T; Okada H; Ogita S; Ozaki M; Hatae M
    Gan To Kagaku Ryoho; 1996 Feb; 23(3):317-25. PubMed ID: 8712825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 status is neither a predictive nor a prognostic variable in patients with advanced ovarian cancer treated with a paclitaxel-based regimen.
    Gadducci A; Cianci C; Cosio S; Carnino F; Fanucchi A; Buttitta F; Conte PF; Genazzani AR
    Anticancer Res; 2000; 20(6C):4793-9. PubMed ID: 11205220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Weekly paclitaxel therapy for metastatic breast cancer].
    Kokufu I; Taniguchi H; Kimura F; Fukuda K; Yamamoto M; Yano T; Yamada K
    Gan To Kagaku Ryoho; 2002 Feb; 29(2):221-6. PubMed ID: 11865627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma.
    Hsu C; Huang CS; Chao TY; Lu YS; Bu CF; Chen MM; Chang KJ; Cheng AL
    Cancer; 2002 Nov; 95(10):2044-50. PubMed ID: 12412156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Chemotherapy of ovarian and breast cancer with Taxol].
    Dtsch Med Wochenschr; 1996 Dec; 121(50 Suppl):1-12. PubMed ID: 9022362
    [No Abstract]   [Full Text] [Related]  

  • 15. [Second-line chemotherapy with paclitaxel for ovarian cancer].
    Lehoczky O; Bagaméri A; Udvary J; Pulay T
    Orv Hetil; 2001 Oct; 142(42):2299-301. PubMed ID: 11760646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial.
    Buzdar AU; Singletary SE; Valero V; Booser DJ; Ibrahim NK; Rahman Z; Theriault RL; Walters R; Rivera E; Smith TL; Holmes FA; Hoy E; Frye DK; Manuel N; Kau SW; McNeese MD; Strom E; Thomas E; Hunt K; Ames F; Berry D; Hortobagyi GN
    Clin Cancer Res; 2002 May; 8(5):1073-9. PubMed ID: 12006521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Paclitaxel (Taxol)--drug of choice in ovarian cancer].
    Fishman A
    Harefuah; 1996 Apr; 130(8):557-60. PubMed ID: 8765885
    [No Abstract]   [Full Text] [Related]  

  • 18. Paclitaxel and docetaxel in breast and ovarian cancer.
    Drug Ther Bull; 1997 Jun; 35(6):43-6. PubMed ID: 9282422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Taxol--a new cytostatic drug for therapy of ovarian and breast cancer].
    Meden H; Rath W; Kuhn W
    Geburtshilfe Frauenheilkd; 1994 Apr; 54(4):187-93. PubMed ID: 7912212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Weekly Taxol (Paclitaxel) administration in the second-line treatment of breast cancer].
    Dank M
    Magy Onkol; 2002; 46(2):189-91. PubMed ID: 12202898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.